Table 1 Baseline characteristics of the study cohort at the time of recruitment
From: Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD
Characteristic | n = 127 |
|---|---|
Age (years) | 66.8 ± 8.6 |
Male sex, n (%) | 68 (53.5) |
Body mass index (kg/m2) | 27.7 (5.5) |
Smoking status (n, %) | |
 Current smoker | 54 (43.0) |
 Ex-smoker | 73 (57.0) |
Smoking history pack-yearsa | 47.0 (26.3) |
Post-bronchodilator FEV1 (% predicted) | 46.4 ± 15.2 |
FEV1 (Litres) | 1.20 ± 0.47 |
FVC (Litres) | 2.82 ± 0.82 |
GOLD Stage, n (%) | |
 II (moderate) | 57 (44.9) |
 III (severe) | 51 (40.2) |
 IV (very severe) | 19 (15.0) |
Bronchiectasis evident on enrolment HRCT, n (%) | 10 (7.9) |
Frequency of exacerbation reporting in the preceding 12Â months, n (%) | |
 1 exacerbation | 28 (22.0) |
 2 exacerbations | 37 (29.1) |
 3 or more exacerbations | 62 (48.8) |
Number of exacerbations in the preceding 12 months | 3.1 ± 2.3 |
ICS use, n (%) | 113 (89.0) |
LABA use, n (%) | 104 (81.9) |
LAMA use, n (%) | 93 (73.2) |
Influenza vaccination in the preceding 12Â months, n (%) | 114 (89.8) |
Pneumococcal vaccination in the preceding 12Â months, n (%) | 12 (9.4) |